TY - JOUR
T1 - Etiology and Treatment of Urolithiasis
AU - Pak, C. Y C
PY - 1991
Y1 - 1991
N2 - Nephrolithiasis is a heterogeneous disorder, with varying chemical composition and pathophysiologic background. Although kidney stones are generally composed of calcium oxalate or calcium phosphate, they may also consist of uric acid, magnesium-ammonium phosphate, or cystine. Stones develop from a wide variety of metabolic or environmental disturbances, including varying forms of hypercalciuria, hypocitraturia, undue urinary acidity, hyperuricosuria, hyperoxaluria, infection with urease-producing organisms, and cystinuria. The cause of stone formation may be ascertained in most patients using the reliable diagnostic protocols that are available for the identification of these disturbances. Effective medical treatments, capable of correcting underlying derangements, have been formulated. They include sodium cellulose phosphate, thiazide, and orthophosphate for hypercalciuric nephrolithiasis; potassium citrate for hypocitraturic calcium nephrolithiasis; acetohydroxamic acid for infection stones; and d-penicillamine and α-mercaptopropionylglycine for cystinuria. Using these treatments, new stone formation can now be prevented in most patients.
AB - Nephrolithiasis is a heterogeneous disorder, with varying chemical composition and pathophysiologic background. Although kidney stones are generally composed of calcium oxalate or calcium phosphate, they may also consist of uric acid, magnesium-ammonium phosphate, or cystine. Stones develop from a wide variety of metabolic or environmental disturbances, including varying forms of hypercalciuria, hypocitraturia, undue urinary acidity, hyperuricosuria, hyperoxaluria, infection with urease-producing organisms, and cystinuria. The cause of stone formation may be ascertained in most patients using the reliable diagnostic protocols that are available for the identification of these disturbances. Effective medical treatments, capable of correcting underlying derangements, have been formulated. They include sodium cellulose phosphate, thiazide, and orthophosphate for hypercalciuric nephrolithiasis; potassium citrate for hypocitraturic calcium nephrolithiasis; acetohydroxamic acid for infection stones; and d-penicillamine and α-mercaptopropionylglycine for cystinuria. Using these treatments, new stone formation can now be prevented in most patients.
KW - Nephrolithiasis
KW - hypercalciuria
KW - hypocitraturia
UR - http://www.scopus.com/inward/record.url?scp=0026318109&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026318109&partnerID=8YFLogxK
U2 - 10.1016/S0272-6386(12)80602-0
DO - 10.1016/S0272-6386(12)80602-0
M3 - Article
C2 - 1962646
AN - SCOPUS:0026318109
SN - 0272-6386
VL - 18
SP - 624
EP - 637
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 6
ER -